UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000014649
Receipt No. R000016961
Scientific Title A randomized, multicenter, phase II trial comparing neo-adjuvant therapy using pertuzumab and trastuzumab emtansine based on the dual HER2 blockade in patients with operable HER2-positive primary breast cancer(Neo-peaks study)
Date of disclosure of the study information 2014/08/01
Last modified on 2019/09/05 15:15:18

No. Disposal Last modified on Item of update
1 Insert 2014/07/25 18:21:01
2 Update 2014/07/25 18:26:24 UMIN ID1
UMIN ID2
3 Update 2014/07/26 18:54:27 Division name
4 Update 2014/07/26 18:57:05 IND to MHLW
5 Update 2014/07/26 19:02:14 IND to MHLW
6 Update 2014/07/26 19:03:02 IND to MHLW
7 Update 2014/07/28 18:59:25 IND to MHLW
8 Update 2014/07/31 15:48:50 Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
9 Update 2014/08/13 14:09:07 Narrative objectives1
Primary outcomes
Key secondary outcomes
10 Update 2014/08/13 17:20:27 Key inclusion criteria
Key exclusion criteria
11 Update 2014/08/13 17:21:19 Recruitment status
12 Update 2016/05/23 17:10:22 Recruitment status
13 Update 2016/05/23 17:12:30 Name of primary sponsor
Organization
Institutions
14 Update 2016/07/27 15:18:22 Last follow-up date
15 Update 2018/01/26 09:53:33 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
16 Update 2018/08/23 17:43:09 Public title
17 Update 2018/08/24 10:09:50 UMIN ID1
UMIN ID2
18 Update 2019/09/05 15:08:09 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
19 Update 2019/09/05 15:10:54 Number of participants that the trial has enrolled
20 Update 2019/09/05 15:15:18 Date of IRB


Contact us.